Evidence map›Paper›PMID 33951340›Full record

ReviewJournal of cachexia, sarcopenia and muscle2021

Mouse models of sarcopenia: classification and evaluation.

Wen-Qing Xie, Miao He, Deng-Jie Yu, Yu-Xiang Wu, Xiu-Hua Wang, Shan Lv, Wen-Feng Xiao, Yu-Sheng Li

Open access · goldAbstract readReview
In one paragraph

Review in Journal of cachexia, sarcopenia and muscle, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
139citing papers in PubMed, 1 pooled it
16.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

139 citing papers in PubMed, 1 synthesis or guideline pooled it, 219 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Food science & nutrition · 2026
    Article

79 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Wen-Qing XieDepartment of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China.ORCID 0000-0001-9810-7372
Miao HeDepartment of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Deng-Jie YuDepartment of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yu-Xiang WuSchool of Kinesiology, Jianghan University, Wuhan, Hubei, China.
Xiu-Hua WangXiang Ya Nursing School, The Central South University, Changsha, Hunan, China.
Shan LvDepartment of Geriatric Endocrinology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Wen-Feng XiaoDepartment of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yu-Sheng LiDepartment of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Central South University · CNJianghan University · CNJiangsu Province Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcopenia is a progressive and widespread skeletal muscle disease that is related to an increased possibility of adverse consequences such as falls, fractures, physical disabilities and death, and its risk increases with age. With the deepening of the understanding of sarcopenia, the disease has become a major clinical disease of the elderly and a key challenge of healthy ageing. However, the exact molecular mechanism of this disease is still unclear, and the selection of treatment strategies and the evaluation of its effect are not the same. Most importantly, the early symptoms of this disease are not obvious and are easy to ignore. In addition, the clinical manifestations of each patient are not exactly the same, which makes it difficult to effectively study the progression of sarcopenia. Therefore, it is necessary to develop and use animal models to understand the pathophysiology of sarcopenia and develop therapeutic strategies. This paper reviews the mouse models that can be used in the study of sarcopenia, including ageing models, genetically engineered models, hindlimb suspension models, chemical induction models, denervation models, and immobilization models; analyses their advantages and disadvantages and application scope; and finally summarizes the evaluation of sarcopenia in mouse models.

Indexed as

Healthy AgingSarcopeniaAgedAgingAnimalsHindlimb SuspensionHumansMiceMuscle, SkeletalAgeingChemical inductionGenetic engineeringHindlimb unloadingMouse modelSarcopenia

Identifiers

PMID33951340
PMCPMC8200444
OpenAlexW3158552092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.